Form 8-K - Current report:
SEC Accession No. 0001737287-24-000062
Filing Date
2024-10-07
Accepted
2024-10-07 16:28:00
Documents
14
Period of Report
2024-10-03
Items
Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K allo-20241003.htm   iXBRL 8-K 27621
2 EX-14.1 allo-20241003x8kex141.htm EX-14.1 100814
  Complete submission text file 0001737287-24-000062.txt   277548

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20241003.xsd EX-101.SCH 1989
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20241003_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20241003_pre.xml EX-101.PRE 12595
16 EXTRACTED XBRL INSTANCE DOCUMENT allo-20241003_htm.xml XML 2763
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 241358151
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)